QMI supports and manages QMUL’s equity interests in its spinout portfolios. The portfolio currently sits at 11 companies and includes companies listed on the AIM market of the London Stock Exchange.
Provides clinical services, focused on human challenge virus studies, and preclinical analytical services primarily to large, global pharmaceutical companies and biotechnology organisations.
Listed on AIM
Based at Queen Mary's BioEnterprises Innovation Centre
Drug Delivery in inflammation and cancer
Specialises in the supply of chemically functionalised solid materials for separation and purification opportunities in different market sectors
Biomaterials for nerve repair
Prof John Priestly
Phosphoproteomics for biomarker discovery and drug profiling, using a mass spectrometry-based approach to interpretation of cell signaling pathways
Robust video analytics solutions that define meaningful semantic tags for wide scale applications eg detection and tagging of objects in a CCTV scene
Novel thin-film hydrogel material for disposable, rapid protease sensors, with a wide range of potential industrial and healthcare applications
Real-time algorithm-based software tool that predicts service quality experienced by users of a computer network, plus launch of instant automatic diagnostic traces to isolate problems
Social networks information retrieval. Platform enables monitoring and management of brand reputation and marketing campaigns
Dr Matthew Purver, Dr Stuart Battersby, School of Electronic Engineering & Computer Science
Dry powder dispensing technology
Dr Shoufeng Yang, School of Engineering & Materials Science
Automatic music mixing algorithms, replacing the need for a sound engineer and mixing desk
In 2010, QMI was also involved in establishing QApps, QMUL's smart phone app store, and is currently engaged in its ongoing funding and management. The store, which distributes a range of innovative and exciting apps developed by staff and students, covers areas from music to healthcare, in both iPhone and Android formats.